MIA’s Prof Georgina Long AO named as world’s top melanoma expert
Prof Long has been named No 1 Melanoma Expert in worldwide rankings just released by expertscape, based on articles published 2012-2022.
MIA launches world-first tool to predict immunotherapy response
New clinical tool developed by Melanoma Institute Australia hailed a breakthrough in personalising treatment for all cancer patients.
MIA researchers showcase new frontier in melanoma treatment at ASCO 2022
An unprecedented number of breakthroughs to be presented by MIA researchers at world's leading clinical oncology conference.
FDA approves new combination immunotherapy
Australian researchers and patients were critical to trialling this breakthrough new treatment for advanced melanoma patients.
Why we all need to take steps for Melanoma March
Melanoma March 2022 is aiming to raise $1 million for a world-first clinical trial of a Personalised Immunotherapy Platform which could transform melanoma treatment.
State of the Nation – A Report into Melanoma
A landmark report provides status of melanoma in Australia, and the the roadmap to achieve zero deaths from melanoma this decade.
Neoadjuvant therapy, a breakthrough in Stage III melanoma treatment
In what is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy, a new study has revealed that drug treatment before surgery is effective in preventing deadly spread of the disease.
MIA joins Sydney Health Partners
MIA has joined Sydney Health Partners, with a shared focus on more rapidly translating research evidence into patient benefit.
MIA research wins Cancer Institute of NSW ‘Wildfire Highly Cited Publication’
Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.
Medical Directors receive USYD VC’s Award
The 'Outstanding Research Award' recognises their life-saving discoveries transforming melanoma patient care.